Cargando…
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
BACKGROUND: The 2019 novel coronavirus disease (COVID-19) causes for unresolved reasons acute respiratory distress syndrome in vulnerable individuals. There is a need to identify key pathogenic molecules in COVID-19-associated inflammation attainable to target with existing therapeutic compounds. Th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203545/ https://www.ncbi.nlm.nih.gov/pubmed/32380958 http://dx.doi.org/10.1186/s10020-020-00172-4 |